These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
37 related articles for article (PubMed ID: 30412987)
1. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. Park JS; Lee YS; Lee CN; Kim SH; Kim SW; Han SW World J Urol; 2019 Aug; 37(8):1665-1670. PubMed ID: 30511212 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102 [TBL] [Abstract][Full Text] [Related]
5. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659 [TBL] [Abstract][Full Text] [Related]
6. Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9. Lee SR; Park BW; Kim JH Eur Urol; 2019 Mar; 75(3):e57-e58. PubMed ID: 30327271 [No Abstract] [Full Text] [Related]
7. RE: Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Zhou Z; Gao Z Neurourol Urodyn; 2019 Aug; 38(6):1792. PubMed ID: 31157924 [No Abstract] [Full Text] [Related]
8. Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-Blind Multicentre Phase 3B Study (BESIDE). Wein AJ J Urol; 2017 Mar; 197(3 Pt 1):767-768. PubMed ID: 28208543 [No Abstract] [Full Text] [Related]
9. Re: Efficacy and Safety of Combinations of Mirabegron and Solifenacin Compared with Monotherapy and Placebo in Patients with Overactive Bladder (SYNERGY Study). Wein AJ J Urol; 2018 Sep; 200(3):502-505. PubMed ID: 30412987 [No Abstract] [Full Text] [Related]
10. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature]. Moyson J; Legrand F; Vanden Bossche M; Quackels T; Roumeguère T Prog Urol; 2017 Mar; 27(4):203-228. PubMed ID: 28228331 [TBL] [Abstract][Full Text] [Related]